Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (441-450 of 602) with videos related to

Pageof 61
Sort By:
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemiaSurbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Pageof 61

Showing results (441-450 of 602) with videos related to

Sort By:
Pageof 61
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|April 4, 2017
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemiaSurbhi Sidana, S Vincent Rajkumar, Angela Dispenzieri, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Pageof 61